Roche reveals Phase 3 Avastin brain cancer study results
Hannah Blake
pharmaphorum
Roche has announced that its Phase 3 AVAglio study of Avastin has met its co-primary endpoint of significantly improving progression-free survival (PFS) in people with an aggressive form of brain cancer, glioblastoma.
In the clinical trial, Avastin, in combination with radiation and temozolomide chemotherapy, significiantly extended the time people with this aggressive form of brain cancer lived without their disease getting worse, compared to those treated with radiation and temozolomide chemotherapy plus placebo.
Data for the other co-primary endpoint, for overall survival (OS), are expected in 2013.
“This study showed that people with glioblastoma, a particularly devastating and aggressive cancer without many treatment options, lived significantly longer without their disease worsening when Avastin was added to radiation and temozolomide chemotherapy.”
Hal Barron M.D., Chief Medical Officer and Head Global Product Development at Roche.
Roche now plans to discuss these Phase 3 results with global regulatory authorities, including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).
Reference links:
